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Reactive oxygen intermediates (ROI) generated in response to receptor stimulation play an important role in cellular responses.
However, the effect of increased H2O2 on an antigen-specific CD8
 T cell response was unknown. Following T cell receptor
(TCR) stimulation, the expression and oxidation of peroxiredoxin II (PrdxII), a critical antioxidant enzyme, increased in CD8
T cells. Deletion of PrdxII increased ROI, S phase entry, division, and death during in vitro division. During primary acute viral
and bacterial infection, the number of effector CD8 T cells in PrdxII-deficient mice was increased, while the number of memory
cells were similar to those of the wild-type cells. Adoptive transfer of P14 TCR transgenic cells demonstrated that the increased
expansion of effector cells was T cell autonomous. After rechallenge, effector CD8 T cells in mutant animals were more skewed
to memory phenotype than cells fromwild-type mice, resulting in a larger secondary memory CD8 T cell pool. During chronic
viral infection, increased antigen-specific CD8 T cells accumulated in the spleens of PrdxII mutant mice, causing mortality.
These results demonstrate that PrdxII controls effector CD8 T cell expansion, secondary memory generation, and
immunopathology.
CD8 T cells are critical for the immune system’s response toinfectious agents and tumors (3, 53). During an infection,
naïve T cell activation commences upon T cell receptor (TCR)
recognition of cognate antigen presented by major histocompat-
ibility complex (MHC) proteins on the surface of antigen-pre-
senting cells (APCs). Antigenic recognition triggers a signaling
cascade marked by protein tyrosine phosphorylation, increased
generation of reactive oxygen intermediates (ROI), and a rise in
intracellular calcium (20, 33, 37). Together, these signals initiate
effector cell differentiation that is accompanied by increased pro-
tein synthesis, cell growth, and effector functions such as cytokine
production and cytolytic activity (12). Activation also results in
massive clonal expansion beginning 24 h after stimulation and
continuing with one division every 6 to 8 h (35). Upon pathogen
clearance, the immune system returns to homeostasis through
apoptosis of the majority of effector cells, while surviving cells
further differentiate into long-lived memory cells (12). During a
chronic infection, CD8 T cells still expand but gradually lose
effector function through a process termed exhaustion due to per-
sistent antigen exposure, and they fail to differentiate to memory
cells (45). Understanding the mechanisms regulating the function
and differentiation of antigen-specific T cells is essential for de-
signing new vaccine and immunotherapy strategies.
Multiple studies have established a critical role for ROI in reg-
ulating signaling in a variety of cell types. As early as 1979, May
and de Haen demonstrated that H2O2 acts as a “second messen-
ger” during insulin stimulation (31), and in another study it was
found that H2O2 subsequently induces oxidative inactivation of
the tyrosine phosphatase PTP1B to promote signal transduction
(32). In addition, ROI have also been implicated in the regulation
of transcription factors, such as AP-1 (1) and NF- (30, 38), and
kinases such as protein kinase C (15). To prevent oxidative stress,
cells must possess the means to regulate ROI in order to modulate
signal transduction. Peroxiredoxins have been proposed to act as a
cellular switch that determines whether hydrogen peroxide acts as
a deleterious oxidant or a beneficial second messenger through the
use of reducing equivalents provided by thioredoxin (46). Because
of its high affinity for H2O2 (Michaelis constant [Km] for H2O2,
10 M) and abundance in the cytoplasm, peroxiredoxin II
(PrdxII) can modulate receptor signaling pathways while protect-
ing cells from nonspecific oxidation of cellular components (8).
PrdxII expression affects cellular functions such as proliferation,
differentiation, heme metabolism, intracellular signaling, and
chemotherapeutic resistance of cancer cells (10, 11, 28). In the case
of the immune system, deletion of PrdxII has been shown to pro-
mote differentiation of bone marrow cells into CD11c-positive
dendritic cells and to enhance concanavalin A-induced splenocyte
proliferation in vitro (34). However, the contribution of PrdxII
during an adaptive immune response was not determined.
T cell activation and proliferation are highly energetic pro-
cesses in which cells adapt their metabolism (39) and electron
transport (51) to become fully activated. During this phase, the
ROI generated are required for activation and function of CD8T
cells (14, 33). Previous studies demonstrated that antioxidants
inhibit proliferation and interleukin-2 (IL-2) production when
administered during the early stages of T cell activation (9). In
both infectious (27) and autoimmune models (41), antioxidant
treatment has been shown to decrease the proliferation and cyto-
kine production of antigen-specific T cells. Together, these find-
ings suggest that ROI generated in response to receptor stimula-
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tion are positive mediators of lymphocyte activation. In contrast,
high levels of ROI have been implicated with T cell dysfunction in
diseases such as cancer, HIV, and systemic lupus erythematosus
and in aging (7, 13, 25, 40). Therefore, maintaining optimal levels
of ROI is critical to T cell proliferation and function.
We hypothesized that PrdxII, through modulation of ROI, was
a critical regulator of T cell proliferation, function, and differen-
tiation. During the initial stages of CD8 T cell activation, we
observed an increase in both PrdxII expression and oxidation. By
utilizing mice deficient in PrdxII, we present the first report, to our
knowledge, in which the contribution of increased H2O2 to the
antiviral immune response is determined. Along with elevated
ROI levels, we measured increased CD8 T cell division in vitro
and effector cell expansion in vivo in lymphocytic choriomenin-
gitis virus (LCMV)-infected PrdxII/ mice. Surprisingly, the
generation of secondary but not primary memory CD8 T cells
was increased in mutant mice. Lack of PrdxII during chronic
LCMV infection resulted in mortality that was mediated by an
increased expansion of virus-specific CD8 T cells. These results
demonstrate that PrdxII is a regulator of ROI levels and the ex-
pansion of antigen-specific CD8 T cells.
MATERIALS AND METHODS
Mice, virus, bacteria, and infections. PrdxII / mice, described previ-
ously (28), were backcrossed onto the C57BL/6 background for 10 gener-
ations. Wild-type and knockout littermates were separated and used to
generate lines that were maintained by homozygous mating. Genotypes
were confirmed by PCR amplification of tail DNA. P14 PrdxII/ mice
were generated by crossing PrdxII/mice with P14 mice that were main-
tained on a C57BL/6 (CD45.2) background. CD45.1 mice were purchased
from Jackson Laboratory (Bar Harbor, ME). In the adoptive transfer ex-
periments, 6,000 P14 cells were injected intravenously before infection.
For Western blots, naïve C57BL/6 mice were purchased from the National
Cancer Institute (Frederick, MD). All studies were approved by the Insti-
tutional Animal Care and Use Committee (IACUC) of the Wake Forest
University School of Medicine. Six- to eight-week-old mice were infected
with 2  105 PFU of lymphocytic choriomeningitis virus strain Arm-
strong (LCMV-Armstrong) intraperitoneally (i.p.) or 2  106 PFU of
LCMV strain Clone 13 (LCMV-Clone 13) intravenously (i.v.). Virus was
grown and quantitated as previously described (2). For bacterial infection,
6- to 8-week-old mice were infected i.v. with 5  103 CFU of Listeria
monocytogenes expressing the LCMV epitope GP33-41, which was pre-
pared as described previously (52).
Cell isolation. The spleen was removed from mice after cervical dis-
location. Following mechanical disruption of splenocytes on a wire mesh
screen, red blood cells were removed by osmotic lysis in ACK buffer
(NH4Cl, KHCO3, and EDTA). Splenocytes were then resuspended in
RPMI 1640 supplemented with 10% fetal calf serum (FCS), L-glutamine,
penicillin-streptomycin, and -mercaptoethanol (complete medium).
For isolation of liver lymphocytes, mice were euthanized, the abdomen
was opened, the hepatic vein was cut, and 5 ml of ice-cold phosphate-
buffered saline (PBS) was injected directly into the hepatic artery to per-
fuse the liver. The gallbladder was removed, and the entire liver was ex-
cised. The liver tissue was homogenized with a wire screen and incubated
in 0.25 mg of collagenase B/ml (Boehringer Mannheim) and 1 U of DNase
(Sigma)/ml at 37°C for 45 min. Digested liver was centrifuged, and the
pellet was resuspended in 5 to 10 ml of 44% Percoll (Sigma). This solution
was underlain with 56% Percoll and spun at 2,000 rpm for 20 min at 20°C.
The intrahepatic lymphocyte populations were harvested from the inter-
face, and red blood cells were lysed with 0.83% ammonium chloride,
washed, and counted.
CD8 T cell purification. CD8 T cells were negatively selected by
magnetic bead enrichment from the spleens of naïve 6- to 8-week-old
mice using the Miltenyi MicroBead system according to the manufactur-
er’s protocol. Purity was	95% as determined by flow cytometry.
CD8 T cell stimulation. For anti-CD3/CD28 stimulations, 48-well
flat-bottom plates were coated with 10g/ml of anti-CD3 and anti-CD28
antibodies or 20g/ml control IgG in PBS overnight at 4°C. All antibodies
were purchased from BD Pharmingen. After removal of PBS, purified T
cells were added at 3 105 cells per ml. Phorbol myristate acetate (PMA)
and ionomycin (ION) stimulation was induced at 50 ng/ml and 500 ng/
ml, respectively.
Real-time RT-PCR. Purified CD8 T cells (3 105) were stimulated
for the times indicated with anti-CD3 and anti-CD28 antibodies. RNA
was isolated using the RNeasy Minikit (Qiagen), and cDNA was generated
by reverse transcription (RT) (Superscript II; Invitrogen) according to the
manufacturer’s instructions. Real-time PCR was performed on an ABI
Prism 7000 Sequencer and detection system using SDS V1.X software with
TaqMan Gene Expression kits for murine PrdxII (Mm00448996_m1),
c-myc (Mm00487804_m1), and GAPDH (4352932E). Signal was normal-
ized to GAPDH, and the fold increase relative to ex vivo was determined.
Western blotting. To measure PrdxII and Prdx-SO3 levels, 2  10
6
purified CD8 T cells were lysed in 50 mM Tris-HCl, 100 mM NaCl, 2
mM EDTA, 20 mM -glycerophosphate, 0.1% SDS, 0.5% sodium deoxy-
cholate, 0.5% Igepal, 0.5% Triton X-100, 1 mM Na3VO4, 20 mM NaF, 1
mM phenylmethylsulfonyl fluoride (PMSF), 10 g/ml aprotinin, and 10
g/ml leupeptin (pH 8.0). Lysates were immediately sonicated and frozen
at70°C. To measure dimer formation in PrdxII, cells were pretreated for
10 min with 100 mMN-ethylmaleimide (NEM) and subsequently lysed in
the presence of NEM. Samples were then separated on a 12% SDS dena-
turing gel, transferred to a nitrocellulose or polyvinylidene difluoride
(PVDF) membrane, and blocked for 1 h at room temperature in 5% skim
milk. PrdxII and Prdx-SO3 antibodies (Abs) were purchased from Lab
Frontiers and were used at a dilution of 1:4,000 in 5% milk and incubated
with membranes overnight at 4°C. After three washes, the blots were in-
cubated with goat anti-rabbit horseradish peroxidase (HRP)-conjugated
secondary Ab (Southern Biotechnology) at a 1:10,000 dilution in 5% milk
for 2 h at 4°C. The blot was then visualized using the SuperSignal Dura
West Chemiluminescent Substrate from Pierce according to the manu-
facturer’s protocol. The blot was then stripped with Restore Western blot
stripping buffer (Pierce) for 10 min at room temperature, blocked, probed
with anti-actin (Santa Cruz) at a 1:1,000 dilution, and subsequently de-
veloped as described above. For quantitation of protein expression, actin
and PrdxII levels were normalized using a Kodak Image Station 2000RT
and Kodak Molecular Imaging software. The fold increase in PrdxII was
calculated by multiplying the fold difference in the normalized actin value
by the PrdxII signal.
DCFDA oxidation. DCFDA [5-(and-6-)-chloromethyl-2=,7=-dichlo-
rodihydrofluorescein diacetate-acetyl ester] was purchased from Invitro-
gen and resuspended in dimethyl sulfoxide (DMSO) as a 2 mM stock.
Cells were stimulated in a 96-well flat-bottom plate, transferred to a 96-
well round-bottom plate after stimulation, and incubated with DCFDA
for 30 min at 37°C before being washed in fluorescence-activated cell
sorter (FACS) buffer (2% FCS and PBS), stained with anti-CD8
Ab, and
acquired immediately on a FACSCalibur instrument. Data are presented
as changes in mean fluorescent intensities compared with unstimulated
wild-type cells.
Surface and intracellular staining. In this study, the following Abs




-peridinin chlorophyll protein (CD8
-PerCP), rat anti-
mouse CD8
-APC, rat anti-mouse CD127-fluorescein isothiocyanate
(CD127-FITC), rat anti-mouse CD44-FITC, rat anti-mouse CD4-PE, rat
anti-mouse gamma interferon (IFN-)-FITC, rat anti-mouse tumor ne-
crosis factor alpha (TNF-
)-PE, rat anti-mouse IL-2-APC, rat anti-mouse
killer cell lectin-like receptor G1(KLRG1)-PE, rat anti-mouse CD27-PE,
rat anti-mouse CD62L-FITC, rat anti-mouse LAG3-PE, and hamster anti-
mouse PD-1. KLRG1 antibody was purchased from Abcam. CD127 and
PD-1 antibodies were purchased from eBioscience. All other antibodies
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were purchased from BD Pharmingen. DbGP33-41, DbNP396-404, and
DbGP276-286 MHC class I tetramers were generated as previously de-
scribed (36). Surface staining was performed by incubation of Abs at a
1:100 dilution in FACS buffer for 30 min at 4°C. KLRG1 staining was
performed at a 1:25 dilution. To measure intracellular cytokine levels,
cells were treated with BD Biosciences Cytofix/Cytoperm kit according to
the manufacturer’s instructions.
Cell cycle analysis. BrdU (Sigma-Aldrich) labeling was performed as
described previously by Tebo et al. (44). Briefly, purified CD8 T cells
were stimulated with anti-CD3 and anti-CD28 antibodies. During the
final hour of stimulation, samples were pulsed with 10 M BrdU for 60
min, resuspended in 1% paraformaldehyde with 0.05% Igepal (Sigma-
Aldrich), shaken, and incubated overnight at 4°C. Cells were then washed
two times in room temperature PBS at 290 g for 6 min, resuspended in
1 ml of PBS and 4.2 mM MgCl2 containing 50 Kunitz U/ml DNase I
(Sigma-Aldrich), and incubated for 30 min at 37°C. After two washes with
wash buffer (5% FCS with 0.5% Igepal in PBS) at 290  g and 4°C for 6
min, cells were resuspended in the same buffer containing 2% mouse
serum and a 1:5 dilution of anti-BrdU-FITC (BD Pharmingen) and incu-
bated on ice for 45 min. Samples were washed two times in wash buffer at
290  g and 4°C for 6 min. For 7-amino-actinomycin D (7-AAD) stain-
ing, cells were resuspended in 20 l of 7-AAD (Pharmingen) plus FACS
buffer for 10 min on ice. Samples were acquired immediately using a
FACSCalibur instrument.
CFSE labeling. CFSE (5-6-carboxyfluorescein diacetate, succinimidyl
ester) was purchased from Invitrogen Life Technologies and dissolved in
DMSO as a 5 mM stock. After purification, cells were washed three times
in PBS and suspended at a concentration of 2 107 cells/ml in PBS. The
CFSE stock was diluted to 6.67 M in PBS and mixed with cells 1:1 (vol/
vol), resulting in a final concentration of 3.33 M. After 3 min, samples
were vortexed and then incubated for an additional 2 min. After this time,
1/10 volume of FCS was added for 1 min followed by vortexing. The cells
were then washed three times with complete medium and used in exper-
iments. The percentage of cells in the final division was determined with
FlowJo software (Treestar).
In vivo CD8 depletion. To deplete CD8 T cells in vivo, mice were
administered isotype control or 300 g of rat anti-mouse CD8 antibody
clone 2.43 (BioXcell Corp.) at days 2, 0, and 2 postinfection with
LCMV-Clone 13. Control testing demonstrated greater than 98% deple-
tion of CD8 T cells from naïve mice.
Statistical analysis. Data from all experiments were analyzed by the
Student’s t test using Microsoft Excel, and a P value of0.05 was consid-
ered significant.
RESULTS
PrdxII expression increases following naïve CD8T cell activa-
tion. Previous studies have demonstrated that H2O2 generated in
response to naïve T cell activation is an important contributor to
cysteine oxidation and protein signaling (26, 33). Therefore, we
reasoned that CD8 T cells possess a mechanism that regulates
ROI levels to promote signaling, while preventing oxidation of
nonspecific targets. To address this hypothesis, we focused on the
contribution of the antioxidant peroxiredoxin II (PrdxII), a regu-
lator of H2O2, to T cell activation and differentiation. Since H2O2
is produced following T cell stimulation, we wanted to determine
if PrdxII levels increase. Figure 1A demonstrates that following T
cell receptor (TCR) stimulation, naïve CD8 T cells increased
PrdxII steady-state mRNA levels almost 8-fold by 18 h. This in-
crease was not transient and was maintained throughout the stim-
ulation. The kinetics of PrdxII expression were distinct from those
of the oncogene c-Myc, which was rapidly induced at 6 h, peaked
at 18, and had declined by 30 h. Since we observed that mRNA
levels were increased, it was critical to determine changes on a
protein level. Figure 1B and C demonstrate that following TCR
stimulation, naïve CD8 T cells increased PrdxII protein expres-
sion 2-fold by 18 h and 5-fold by 30 h. This increase in PrdxII levels
correlated with S-phase entry and T cell proliferation (33).
In the presence of H2O2, PrdxII becomes oxidized to sulfenic
acid on the peroxidatic cysteine. This residue then undergoes nu-
cleophilic attack by the resolving cysteine on a neighboring PrdxII
monomer and generates a disulfide bond that can subsequently be
reduced in the presence of thioredoxin and thioredoxin reductase
(47). To determine if PrdxII dimerization is altered during T cell
activation, we measured disulfide bond formation by polyacryl-
amide gel electrophoresis under nonreducing conditions follow-
ing TCR stimulation (Fig. 1D). The greatest increase in PrdxII
dimerization was detected by 18, 24, and 30 h and indicates an
important role for PrdxII in eliminating H2O2 during activation
and proliferation.
When ROI are produced in a concentrated manner, the flood-
gate hypothesis predicts that PrdxII becomes irreversibly oxidized
to sulfinic (SO2) or sulfonic (SO3) acid (46). This prevents disul-
fide bond formation and allows the accumulation of H2O2 within
the cell to promote signaling. To determine if PrdxII undergoes
overoxidation in response to T cell activation, we measured the
levels of PrdxIISO3 utilizing a PrdxSO3 antibody that recognizes
the sulfinic and sulfonic acid forms of PrdxI, II, III, and IV. Within
6 h of activation, there was an increase in PrxIISO3 levels (Fig. 1E)
that continued to increase for the duration of the stimulation. We
also observed that peroxiredoxins I, III, and IV were overoxidized
following stimulation. Together, these data demonstrate that both
PrdxII expression and oxidation increase during naïve CD8 T
cell activation and proliferation.
PrdxII/CD8Tcells generate increasedROI andundergo
more proliferation than wild-type cells. Since increased PrdxII
expression correlated with T cell activation, we hypothesized that
deletion of PrdxII would increase ROI levels. To address this ques-
tion, we used mice that were deficient in PrdxII. To measure ROI
production following T cell activation, we used the oxidant-sen-
sitive dye DCFDA, which is cell permeant and nonfluorescent
until oxidized by peroxides, peroxynitrite, and/or hydroxyl radi-
cals. Within 15 min of stimulation, there was a 20% increase in
DCFDA oxidation in wild-type CD8 T cells. As predicted, the
PrdxII/ T cells possessed even higher levels of DCFDA oxida-
tion both before and following stimulation (Fig. 2A). These results
demonstrate that PrdxII is an important antioxidant protein in
CD8 T cells and regulates intracellular ROI levels.
Prior studies have documented that antioxidants can suppress
lymphocyte proliferation in vitro and in vivo (9, 27, 41). To deter-
mine if increasing ROI promoted S-phase entry, purified CD8 T
cells were activated with anti-CD3 and anti-CD28 antibodies and
were pulsed with BrdU. After intracellular staining, cells were in-
cubated with 7-AAD to determine cell cycle progression. Follow-
ing 18 h of stimulation, 8.9% of wild-type CD8 T cells (Fig. 2B
and C) were in S phase. By 24 h, 70.5% of cells had progressed to S
phase. This contrasts with mutant CD8 T cells, of which 25.9%
had entered S phase by 18 h. When results were quantitated from
multiple experiments (Fig. 2C), they indicated that mutant cells
entered S phase earlier but progressed through at a similar rate. To
determine how loss of PrdxII affects division, CD8 T cells were
purified and CFSE labeled. T cells were then stimulated with anti-
CD3 and anti-CD28, and proliferation was assessed by the loss of
CFSE fluorescence in comparison to undivided cells (Fig. 2D).
Although cells from both genotypes underwent extensive division,
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there were always more PrdxII/ cells in the final division
(Fig. 2D and E). Because division was increased, it was critical to
determine how this affected cell numbers. To verify that
PrdxII/ cells were not more susceptible to cell death in vitro, the
number of viable cells following isotype stimulation was deter-
mined (Fig. 2F), and no difference between wild-type and mutant
cells was observed. This contrasted with the results following anti-
CD3 and anti-CD28 antibody stimulation. Initially, cell numbers
were similar for wild-type and mutant cells. But as time pro-
gressed, wild-type cells preferentially accumulated compared to
PrdxII/ cells (Fig. 2G). Thus, loss of PrdxII promotes S-phase
entry and increased division but results in decreased survival in
vitro.
Increased expansion of primary effector CD8 T cells in
PrdxII/ mice. To determine the importance of increased ROI
production during a primary immune response, wild-type or
PrdxII/ mice were infected with LCMV-Armstrong. Prior to
infection, the number and development of T and B cells in the
bone marrow and thymus were not significantly different for wild-
type and for PrdxII/ mice (data not shown). Figure 3A shows
that the overall number of CD8 T cells in the spleen was slightly
elevated, but this difference was not significant. When naïve
(CD44low) and activated/memory phenotype (CD44high) CD8 T
cells were examined, there was a slight increase (20%) in the
number of activated/memory phenotype cells in PrdxII/ mice.
LCMV-Armstrong is a natural mouse pathogen that replicates in
multiple tissues. When the initial viral replication on days 1 and 3
postinfection was examined (Fig. 3B), similar levels were observed
in the two strains of mice. On day 8 postinfection, at the peak of T
cell expansion, we observed an2-fold increase in the number of
LCMV-specific CD8 T cells in the spleens (Fig. 3C) and livers
(Fig. 3D) of PrdxII/ mice. Studies by Joshi and colleagues have
demonstrated that the effector pool can be subdivided based on
the expression of IL-7 receptor 
 chain (CD127) and killer cell
lectin-like receptor G1 (KLRG1) (24). Short-lived effector cells
(SLEC) are CD127lowKLRG1high and are not maintained follow-
ing infection. Double-positive effector cells (DPEC) are
CD127highKLRG1high, while long-lived memory precursor effec-
tor (MPEC) cells are CD127highKLRG1low. The effector and mem-
ory CD8T cell pools can also be subdivided based on the expres-
FIG 1 PrdxII expression and oxidation increase following naïve CD8 T cell activation. Naïve CD8 T cells were purified by magnetic microbeads and
stimulated (Stim) with anti-CD3 and anti-CD28 antibodies for the indicated times prior to lysis. (A) mRNA was isolated, and expression levels of PrdxII,
c-myc, and GAPDH were determined by RT-PCR. Data are depicted as the fold increase in expression relative to unstimulated samples after normalization
to the GAPDH signal. (B) Protein lysates were prepared, and representative blots indicating total PrdxII (top panel) and actin (bottom panel) expression
are displayed. (C) Data are depicted as the fold increase in PrdxII expression relative to unstimulated cells after normalization to the actin signal. Averages
and standard deviations are shown. (D) Samples were prepared in the presence of N-ethylmaleimide and resolved under nonreducing conditions to detect
PrdxII monomer (20 kDa) and dimer (40 kDa). (E) The blot from panel B was stripped and probed for the overoxidized form of Prdx, PrdxSO3. Data
are representative of a minimum of 3 independent experiments. *, significant difference between stimulated and ex vivo samples; P  0.05. IB,
immunoblot.
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sion of CD62L and CD27. Expression of both sets of surface
markers (Fig. 3E and F) was similar on LCMV-specific CD8 T
cells for wild-type and for PrdxII/ mice. When results were
quantitated from multiple experiments (Fig. 3G and H), a small
difference in SLEC and DPEC was observed only in the GP33-41-
specific CD8 T cells in PrdxII/ mice. No differences were ob-
served in cytokine production (data not shown). Thus, during
primary infection PrdxII/ mice have increased numbers of ef-
fector CD8 T cells that differentiate normally.
Following the peak of the antigen-specific CD8 T cell re-
sponse on day 8, a contraction phase ensues and reaches a memory
set point by 35 days postinfection. Although effector CD8 T cells
were modestly increased, the number of antigen-specific CD8 T
cells declined over time to a similar level in PrdxII/ mice. Once
the memory set point was reached, stable numbers were main-
tained in both genotypes for up to 1 year (Fig. 4A). When the liver
was examined at day 35 postinfection, similar numbers of LCMV-
specific CD8 T cells were observed in the two strains of mice
(data not shown).
Because we observed these increases during an acute viral
infection, it was important to verify whether these effects could
be observed in other infectious models. To address this ques-
tion, mice were infected with Listeria monocytogenes expressing
the GP33-41 epitope from LCMV. At the peak of the response
on day 7, the number of effector CD8 T cells was increased
2-fold (Fig. 4B) in PrdxII/ mice, but the set point following
FIG 2 PrdxII/T cells exhibit increased ROI production and undergo increased proliferation and death following activation. Naïve CD8T cells were purified
by magnetic microbeads from wild-type and PrdxII/ mice. Cells were then stimulated with PMA and ION followed by incubation with DCFDA. (A) Data are
presented as the percent increase in DCFDA MFI compared to unstimulated wild-type cells. The averages and standard deviations are shown. Cells were
stimulated with anti-CD3 and anti-CD28 antibodies at the indicated time points, and BrdU was added for the last hour of culture. Cells were stained with
anti-BrdU antibody and 7-AAD. (B) A representative dot plot of BrdU and 7-AAD staining is shown. The top gate indicates the percentage of cells in S phase. (C)
Data are depicted as the percentage of cells in S phase; averages and standard deviations were plotted. (D) Division of wild-type and PrdxII/CD8 T cells was
assessed by loss of CFSE fluorescence after activation. The brackets on days 2 and 3 indicate the final division. (E) The percentage of cells in each population that
were in the final division was determined, and the averages and standard deviations were plotted. (F and G) The number of viable cells was determined by trypan
blue exclusion assay following isotype (F) or anti-CD3 and anti-CD28 (G) stimulation. Three to six mice were analyzed for each genotype in two to four
independent experiments. *, significant difference between PrdxII/ and wild-type samples; P 0.05.
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the contraction phase was similar. To determine if these
changes were T cell autonomous, P14 TCR transgenic mice that
lacked PrdxII/were generated. Naïve wild-type or PrdxII/
P14 cells (n  6,000) were transferred to naïve CD45.1
congenic recipients, which were then infected with LCMV-
Armstrong. During early infection, responses were modestly
increased in mice that had received PrdxII/ P14 cells, but by
day 7 responses were2-fold greater than those found in mice
that received wild-type P14 cells. From day 7 to day 8 postin-
fection, PrdxII/ P14 cells began to contract, while the num-
ber of wild-type P14 cells plateaued. Following day 8, both
populations declined, reaching a similar memory set point by
day 35 (Fig. 4C). Taken together, these results suggest that loss
of PrdxII increases primary effector CD8 T cell responses in
an autonomous fashion.
Loss of PrdxII increases secondary effector CD8 T cell re-
sponses and alters surface marker phenotype. To determine if
the remaining antigen-specific CD8 T cells following acute in-
fection were “bona fide” memory CD8 T cells, mice that were
previously infected with LCMV-Armstrong 97 days earlier were
challenged with LCMV-Clone 13. After infection, unimmunized
mice of both genotypes had viral titers of108 PFU/g (Fig. 5A) in
their spleens 5 days postinfection, while mice that had been pre-
viously infected with strain Armstrong cleared the infection.
When the number of antigen-specific CD8 T cells was deter-
mined, secondary effector responses were increased 2-fold in
PrdxII/ mice for all three epitopes examined (Fig. 5B). Upon
secondary infection, memory CD8 T cells redifferentiate into
secondary effector cells. Regardless of antigen specificity, CD8 T
cells were skewed in their differentiation toward a more “memory-
like” phenotype with fewer SLECs and more MPECs in PrdxII/
mice (Fig. 5C). This phenomenon was not restricted solely to
KLRG1 and CD127, as similar results were observed when the
markers CD62L and CD27 were analyzed (Fig. 5D). Thus, loss of
FIG 3 Increased expansion of PrdxII/ effector CD8 T cells during primary viral infection. (A) Naïve 6- to 8-week-old wild-type or PrdxII/ mice were
sacrificed, and the numbers of total, naïve (CD44Low), and activated/memory phenotype (CD44High) CD8 T cells in the spleen were determined; the averages
and standard deviations were plotted. (B) Wild-type or PrdxII/ mice were infected with LCMV-Armstrong and the viral titer in the indicated organs was
determined on days 1 and 3 postinfection by plaque assay. The bar indicates the mean. (C and D) Mice were sacrificed on day 8 postinfection, and splenocytes
(C) or liver lymphocytes (D) were stained with anti-CD8
 and the MHC class I tetramers DbGP33-41, DbNP396-404, or DbGP276-286, and the averages and
standard deviations were plotted. On day 8 postinfection, splenocytes were stained with anti-CD8
, MHC class I tetramers DbGP33-41, DbNP396-404, or
DbGP276-286, and either anti-KLRG1 and CD127 (E) or anti-CD62L and CD27 (F). The dot plots are gated on CD8 Tetramer cells, and the number in each
quadrant indicates the percentage of each population. (G and H) The averages and standard deviations were plotted for each population. Five to 10 mice were
analyzed for each genotype in two to four independent experiments. *, significant difference between PrdxII/ and wild-type samples; P 0.05.
FIG 4 Increased expansion of effector CD8 T cells but similar memory set point in PrdxII/ mice following primary viral and bacterial infection. Naïve 6- to
8-week-old wild-type or PrdxII/ mice were infected with LCMV-Armstrong. (A) Mice were sacrificed at various time points following infection, and the
number of CD8 Tetramer T cells was determined in the spleen. (B) To assess effects during acute bacterial infection, mice were inoculated with Listeria
monocytogenes expressing the GP33-41 epitope and sacrificed at the indicated time points. The number of CD8 IFN- T cells in the spleen following GP33-41
peptide stimulation was determined. (C) Naïve P14 wild-type or PrdxII/ cells (n  6,000) were adoptively transferred into congenic (CD45.1) hosts and
infected with LCMV-Armstrong. At the time points indicated, the spleen was examined, and the numbers of CD45.2CD8DbGP33-41 T cells (averages and
standard deviations) were plotted. Five to 10 mice were analyzed for each genotype in two to four independent experiments. *, significant difference between
PrdxII/ and wild-type samples; P 0.05.
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PrdxII increases the magnitude of secondary effector CD8 T cell
responses and alters their differentiation to a more memory-like
phenotype.
Loss of PrdxII increases the secondary memory CD8 T cell
pool and alters their phenotype.Because the number and pheno-
type of secondary effector CD8 T cells were altered, we deter-
mined whether the secondary memory pool was affected. Thirty-
five days following LCMV-Clone 13 rechallenge, the spleen was
harvested and the number of virus-specific CD8 T cells was de-
termined (Fig. 6A). During secondary responses, DbNP396-404-
and DbGP276-286-specific CD8 T cells undergo greater expan-
sion than DbGP33-41 T cells (16, 44). By day 60, we observed a
3-fold increase in NP396-404-specific cells, while GP276-286 cells
were only increased 1.5-fold. Surprisingly, there was no difference
in GP33-41-specific CD8 T cells. In addition to increased num-
bers, secondary memory cells have been shown to be phenotypi-
FIG 5 Loss of PrdxII alters effector CD8 T cell phenotype during secondary infection. Naïve 6- to 8-week-old wild-type or PrdxII/ mice were infected with
LCMV-Armstrong. On day 97 postinfection, LCMV-Armstrong immune mice were rechallenged with LCMV-Clone 13. (A) Mice were sacrificed on day 5
postchallenge, and viral titers were determined in the spleen by plaque assay. Spleens were also analyzed from naïve mice that had been infected with LCMV-
Clone 13 5 days earlier. (B) To determine the numbers of secondary effector cells, splenocytes were stained with anti-CD8
 and MHC class I tetramers, and the
averages and standard deviations were plotted. To examine surface marker phenotypes, splenocytes were stained with anti-CD8
, MHC class I tetramer, and
either anti-CD127 and anti-KLRG1 (C) or anti-CD27 and anti-CD62L (D). The averages and standard deviations were plotted. Five to 10 mice were analyzed for
each genotype in four independent experiments. *, significant difference between PrdxII/ and wild-type samples; P 0.05.
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cally different from primary memory cells (22). To measure func-
tional differences, we performed intracellular cytokine staining
for IFN-, TNF-
, and IL-2 following peptide restimulation. Sim-
ilar to results obtained with MHC class I tetramer staining, the
number of IFN--producing CD8 T cells was increased in
PrdxII/ mice (Fig. 6B). When secondary memory CD8 T cells
were restimulated from wild-type mice, the vast majority pro-
duced both IFN- and TNF-
 (Fig. 6C and D). This contrasted
with PrdxII/ secondary memory CD8 T cells, in which the
production of TNF-
 was significantly decreased. In addition to
TNF-
, memory CD8 T cells also produce IL-2. Following pep-
tide restimulation, more IL-2 production was observed in
PrdxII/ secondary memory cells (Fig. 6E and F). When the
surface phenotype of the secondary memory cells was interro-
FIG6 Loss of PrdxII increases the size and alters the quality of the secondary memory CD8T cell pool. Naïve 6- to 8-week-old wild-type or PrdxII/mice were
infected with LCMV-Armstrong. On day 91 postinfection, LCMV-Armstrong immune mice were rechallenged with LCMV Clone 13. Mice were sacrificed on day
35 postchallenge. (A) Splenocytes were stained with anti-CD8
 and MHC class I tetramers, and the averages and standard deviations were plotted. (B)
Splenocytes were stimulated with the indicated peptide, and the number of IFN--producing CD8T cells was determined. The averages and standard deviations
were plotted. (C and E) In addition to IFN-, the production of TNF-
 (C) or IL-2 (E) was determined. Dot plots are gated on CD8 T cells, and the number
indicates the percentage in each quadrant. (D and F) The percentage of IFN-TNF-
 (D) or IFN-IL-2 (F) cells was quantitated for each epitope, and the
averages and standard deviations were plotted. (G) To examine surface marker phenotype, splenocytes were stained with anti-CD8
, MHC class I tetramer,
anti-CD127, and anti-KLRG1. The averages and standard deviations were plotted. Five mice were analyzed for each genotype in two independent experiments.
*, significant difference between PrdxII/ and wild-type samples; P 0.05.
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gated, there were more CD127highKLRG1low virus-specific CD8
T cells in PrdxII/ mice regardless of antigen specificity
(Fig. 6G). Taken together, these results demonstrate that loss of
PrdxII alters the size and differentiation of the secondary memory
CD8 T cell pool.
Increased expansion of antigen-specific CD8 T cells causes
lethality during chronic infection. Because T cell stimulation is
accompanied by increased ROI production, we hypothesized that
PrdxII would play a critical role during repeated TCR stimulation.
Wild-type and PrdxII/ mice were infected with LCMV-Clone
13, which induces a chronic infection that persists in the brain and
kidneys of mice for extended periods. Infection of wild-type mice
with Clone 13 was not associated with mortality. However, in
PrdxII/ mice mortality was observed by day 9, and within 13
days postinfection almost all of the mice were dead (Fig. 7A).
When viral loads were examined in the spleen and liver, no differ-
ences were observed between wild-type and PrdxII/ mice (Fig.
7B). Enumeration of the effector CD8 T cell response on day 10
postinfection revealed a 2-fold increase across multiple antigen
specificities in PrdxII/ mice (Fig. 7C). During chronic infec-
tion, virus-specific CD8 T cells undergo a process termed ex-
haustion (45). Although functional effector cells are initially gen-
erated, they progressively lose the ability to produce IL-2, TNF-
,
and then IFN-. When cytokine production was examined (Fig.
7D and E), CD8 T cells from both wild-type and PrdxII/ T
cells had manifested loss of function. Since multiple reports have
documented a role for the inhibitory receptors PD-1 (4) and
LAG-3 (5) in regulating T cell function during chronic infection,
FIG 7 PrdxII/ mice die from CD8 T cell-mediated pathology during chronic viral infection. Naïve 6- to 8-week-old wild-type or PrdxII/ mice were
infected with LCMV-Clone 13. (A) The survival of infected animals was recorded for 25 days postinfection. (B) Viral titers in the spleens and livers were
determined by plaque assay on day 10 postinfection. (C) To enumerate antigen-specific effector CD8T cells, splenocytes from day 10 postinfection were stained
with anti-CD8
 and MHC class I tetramers, and the averages and standard deviations were plotted. (D and E) At day 10 postinfection, splenocytes were
stimulated with the indicated peptides followed by surface staining for CD8 and intracellular staining for IFN- and TNF-
 (D) or IFN- and IL-2 (E). The dot
plot is gated on CD8 T cells, and the number indicates the percentage of each population present in that quadrant. (F) Inhibitory receptor expression was
measured in CD8DbGP33-41 T cells. The histograms for each receptor are gated on CD8DbGP33-41 T cells, and the gray overlay is the staining of naïve
(CD44low) phenotype cells. The values indicated are the mean fluorescent intensities of infected and naïve phenotype, respectively. (G) Mice were administered
300g of either isotype control or anti-CD8
 at day2, 0, and 2 postinfection, and survival was monitored for 25 days postinfection (x axis units are days). The
averages and standard deviations were plotted for 6 to 17 mice in two independent experiments. *, significant difference between PrdxII/ and wild-type
samples; P 0.05.
Michalek et al.












we measured the surface expression of these molecules on CD8
DbGP33-41T cells (Fig. 7F). For both markers the level of inhib-
itory receptors was higher on mutant than on wild-type T cells.
Because we observed increased numbers of effector CD8 T cells
in PrdxII/ mice, we reasoned that these cells were causing im-
munopathology. To address this hypothesis, CD8 T cells were
depleted by anti-CD8
 antibody injection on days2, 0, and2
relative to LCMV-Clone 13 infection. This resulted in	98% de-
pletion of CD8 T cells. Antibody depletion completely rescued
PrdxII/ mice from death, while all of the isotype-treated ani-
mals succumbed from days 9 to 11 postinfection (Fig. 7G). Thus,
loss of PrdxII increases effector CD8 T cell expansion during
chronic infection, causing lethal immunopathology.
DISCUSSION
In this study, we examined the role of the antioxidant PrdxII in
promoting CD8 T cell activation, proliferation, and differentia-
tion during viral infection. Here we report five novel observations.
First, PrdxII mRNA, protein levels, and oxidation increased in
response to naïve CD8T cell activation, and this modulated ROI
levels in cells. Second, elevated ROI in PrdxII/ mice were ac-
companied by increased CD8 T cell proliferation both in vitro
and in vivo. Third, increased effector expansion in vivo was T cell
autonomous. Fourth, during secondary infection, lack of PrdxII
skewed the differentiation of effector CD8 T cells to a more
“memory-like” phenotype, resulting in a larger and altered sec-
ondary memory pool. Fifth, during chronic infection, lack of
PrdxII increased the expansion of antigen-specific CD8 T cells,
resulting in lethal immunopathology. Taken together, these re-
sults demonstrate that PrdxII and its regulation of ROI are critical
in controlling CD8 T cell responses.
Prior studies from our laboratory and others have demon-
strated that naïve T cell activation is accompanied by ROI produc-
tion (14, 33). These changes are critical because antioxidant treat-
ment, which lowers ROI, decreases activation and proliferation
(9). However, T cells must possess mechanisms to allow signaling
but limit oxidative damage. Here we report that in response to
naïve CD8 T cell activation, PrdxII mRNA and protein increase.
The changes in mRNA occur relatively late compared to the on-
cogene c-myc and suggest that there are two waves of PrdxII func-
tion: an initial buffering of signaling by protein present at activa-
tion and then a later increase that blocks oxidative damage as cells
begin to divide. By generating a disulfide bond with another
monomer, PrdxII can efficiently catalyze the elimination of intra-
cellular H2O2. Indeed, loss of PrdxII increased the resting and
stimulated levels of H2O2. The presence of dimer that we observe
in naïve CD8T cells stands in contrast to prior studies of immor-
talized Jurkat T cells (29). In those experiments, dimerization was
weakly detected in untreated cells and lost as exogenous H2O2 was
increased. Therefore, during a physiologic response, the regula-
tion of PrdxII dimerization is more important to T cell physiology
than previously estimated and illustrates an important difference
between redox regulation in primary versus transformed cells.
Levels of overoxidation of multiple Prdx proteins also rose, fur-
ther indicating that these proteins are undergoing sustained enzy-
matic turnover in the presence of high levels of H2O2.In addition
to dimerization and overoxidation, we also observed the presence
of higher-order-molecular-weight complexes between PrdxII and
other cellular proteins in activated T cells (Fig. 1D). This suggests
that PrdxII could influence T cell activation and proliferation
through heterologous interactions such as those observed with
platelet-derived growth factor (PDGF) (10) and sulfiredoxin (23).
Taken together, these results indicate that PrdxII is critical for
regulation of H2O2 following T cell activation.
Aside from increased ROI production in PrdxII/ mice, we
also observed a greater expansion of CD8T cells both in vitro and
in vivo. Prior studies of PrdxII/ mice demonstrated increased
proliferation of splenocytes in response to concanavalin A stimu-
lation or of smooth muscle cells during vascular remodeling (10,
34). Here we extend these studies, demonstrating that PrdxII/
CD8 T cells undergo more division due to earlier entry into S
phase. In agreement, we observe a greater expansion of CD8 T
cells in response in vivo to physiologically relevant infections. We
observed 2-fold-greater numbers during acute and chronic infec-
tions of PrdxII/ mice. Given that LCMV infection induces one
of the largest expansions of CD8 T cells, PrdxII’s importance is
illustrated by the further amplification of the response. These re-
sults contrast with earlier studies utilizing antioxidants. By phar-
macologically lowering ROI levels in vivo, decreased CD8 T cell
expansion, contraction, and cytokine production during an acute
LCMV infection (27) or inducible diabetes model (41) were ob-
served.
Our results have important implications for antiviral immune
responses. Taken as a whole, they argue that redox regulation of
CD8 T cell activation and differentiation is complex. Although
the elevation in primary effector CD8 T cell responses in
PrdxII/ mice was not sustained, immunological memory was
maintained for extended periods, suggesting that multiple mech-
anisms help to prevent oxidative stress from driving cells to senes-
cence or apoptosis. In addition to its antiapoptotic properties,
Bcl-2 can function in an antioxidant pathway to prevent cell death
(18). In the absence of PrdxII, high levels of Bcl-2 in memory cells
(17) could prevent both apoptosis and oxidative stress. Addition-
ally, while we did not observe a major alteration in cell phenotype
during primary infection, secondary effector CD8 T cells dis-
played surface marker expression that was skewed to a memory
phenotype, resulting in an expanded secondary memory pool that
displayed altered cytokine production and surface phenotype. Ef-
fector and memory cell fate is controlled by multiple signals (12),
including antigen stimulation, costimulation, and inflammatory
cytokines that converge on the transcription factors T-bet, Eome-
sodermin (Eomes), Blimp-1, Id2, Id3, and Bcl-6 (19, 21, 24, 42,
50). Our observations of increased “memory-like” phenotype ef-
fector CD8 T cells during secondary LCMV infection are similar
to those observed during infection of Blimp1/ mice (42). This
suggests that under conditions where infection is limited, such as
a secondary challenge, increased ROI are beneficial for memory
differentiation, perhaps through increased oxidation of Blimp-1.
Since the DNA-binding activity of multiple transcription factors,
including AP-1 and NF-B, has been shown to be controlled
through oxidation in the cytoplasm and reduction in the nucleus
(43, 48), loss of PrdxII could lead to Blimp-1 overoxidation and
inactivation of its DNA binding. When the secondary memory set
point was reached, the pool was increased in PrdxII/ mice.
Prior studies have demonstrated that secondary memory cells dis-
play decreased CD62L and IL-2 production compared to memory
cells generated following primary infection (22). Loss of PrdxII
actually increased the production of IL-2, and no difference was
observed in CD62L levels (data not shown). In contrast to the
positive effect on IL-2 production, loss of PrdxII negatively regu-
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 production in secondary memory cells. This result
contrasts with previous studies demonstrating that loss of PrdxII
can enhance TNF-
 production in macrophages following lipo-
polysaccharide (LPS) stimulation (49). The role of PrdxII in reg-
ulating CD8 T cell responses was not restricted solely to acute
infection, as we observed increased lethality during chronic
LCMV infection of mutant mice that was mediated by CD8 T
cells. Although we observed increased numbers of effector CD8
T cells in PrdxII/ mice, these cells were not more functional
than their wild-type counterparts and actually had increased in-
hibitory receptor expression. Further confirmation that cytokine
differences may not be the critical defect was provided by etaner-
cept treatment, which failed to rescue PrdxII/mice from lethal-
ity (data not shown). Our results with chronic LCMV contrast
with the increased lethality observed during acute influenza virus
infection of mice that possess a T cell-specific deletion of manga-
nese superoxide dismutase. In this study, Case and colleagues (6)
demonstrated that increased ROI, specifically superoxide, de-
creased the number of antigen-specific effector CD8 T cells dur-
ing infection, causing death. Taken together with our data dem-
onstrating increased H2O2 augmenting responses, these results
argue that the effects of ROI on CD8 T cell activation and differ-
entiation are complex and intermediates may have distinct bio-
logical effects.
In conclusion, we demonstrate that PrdxII is required for reg-
ulating the immune response and mediating survival during
chronic infection. These results have important implications for
regulating immune responses. During chronic viral infection, ma-
nipulation of PrdxII, once the virus and immune system have
reached equilibrium, could lead to increased T cell number and
viral clearance. In addition, modulation of PrdxII could increase
recruitment and expansion of CD8T cells following vaccination.
Together, our results suggest that PrdxII may make an attractive
therapeutic target for modulating the proliferation and expansion
of CD8 T cells.
ACKNOWLEDGMENTS
This work was supported by NIAID grant RO1-AI068952 to J.M.G. and
NCI and NIGMS grants CA126659 and GM050389 to L.B.P. R.D.M. and
K.E.C. were supported by NIAID grant 5T32AI007401-20.
REFERENCES
1. Abate C, Patel L, Rauscher FJ III, Curran T. 1990. Redox regulation of
fos and jun DNA-binding activity in vitro. Science 249:1157–1161.
2. Ahmed R, Salmi A, Butler LD, Chiller JM, Oldstone MB. 1984. Selection
of genetic variants of lymphocytic choriomeningitis virus in spleens of
persistently infected mice. Role in suppression of cytotoxic T lymphocyte
response and viral persistence. J. Exp. Med. 160:521–540.
3. Alexander-Miller MA. 2005. High-avidity CD8 T cells: optimal soldiers
in the war against viruses and tumors. Immunol. Res. 31:13–24.
4. Barber DL, et al. 2006. Restoring function in exhausted CD8 T cells
during chronic viral infection. Nature 439:682– 687.
5. Blackburn SD, et al. 2009. Coregulation of CD8 T cell exhaustion by
multiple inhibitory receptors during chronic viral infection. Nat. Immu-
nol. 10:29 –37.
6. Case AJ, et al. 2011. Elevated mitochondrial superoxide disrupts normal
T cell development, impairing adaptive immune responses to an influenza
challenge. Free Radic. Biol. Med. 50:448 – 458.
7. Cayota A, Vuillier F, Gonzalez G, Dighiero G. 1996. In vitro antioxidant
treatment recovers proliferative responses of anergic CD4 lymphocytes
from human immunodeficiency virus-infected individuals. Blood 87:
4746 – 4753.
8. Chae HZ, Kim HJ, Kang SW, Rhee SG. 1999. Characterization of three
isoforms of mammalian peroxiredoxin that reduce peroxides in the pres-
ence of thioredoxin. Diabetes Res. Clin. Pract. 45:101–112.
9. Chaudhri G, Clark IA, Hunt NH, Cowden WB, Ceredig R. 1986. Effect
of antioxidants on primary alloantigen-induced T cell activation and pro-
liferation. J. Immunol. 137:2646 –2652.
10. Choi MH, et al. 2005. Regulation of PDGF signalling and vascular re-
modelling by peroxiredoxin II. Nature 435:347–353.
11. Chung YM, Yoo YD, Park JK, Kim YT, Kim HJ. 2001. Increased
expression of peroxiredoxin II confers resistance to cisplatin. Anticancer
Res. 21:1129 –1133.
12. Cui W, Kaech SM. 2010. Generation of effector CD8 T cells and their
conversion to memory T cells. Immunol. Rev. 236:151–166.
13. Das R, Ponnappan S, Ponnappan U. 2007. Redox regulation of the
proteasome in T lymphocytes during aging. Free Radic. Biol. Med. 42:
541–551.
14. Devadas S, Zaritskaya L, Rhee SG, Oberley L, Williams MS. 2002.
Discrete generation of superoxide and hydrogen peroxide by T cell recep-
tor stimulation: selective regulation of mitogen-activated protein kinase
activation and fas ligand expression. J. Exp. Med. 195:59 –70.
15. Gopalakrishna R, Gundimeda U, Schiffman JE, McNeill TH. 2008. A
direct redox regulation of protein kinase C isoenzymes mediates oxidant-
induced neuritogenesis in PC12 cells. J. Biol. Chem. 283:14430 –14444.
16. Grayson JM, Harrington LE, Lanier JG, Wherry EJ, Ahmed R. 2002.
Differential sensitivity of naive and memory CD8 T cells to apoptosis in
vivo. J. Immunol. 169:3760 –3770.
17. Grayson JM, Zajac AJ, Altman JD, Ahmed R. 2000. Cutting edge:
increased expression of Bcl-2 in antigen-specific memory CD8 T cells. J.
Immunol. 164:3950 –3954.
18. Hockenbery DM, Oltvai ZN, Yin XM, Milliman CL, Korsmeyer SJ.
1993. Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell
75:241–251.
19. Ichii H, et al. 2002. Role for Bcl-6 in the generation and maintenance of
memory CD8 T cells. Nat. Immunol. 3:558 –563.
20. Imboden JB, Weiss A. 1987. The T-cell antigen receptor regulates sus-
tained increases in cytoplasmic free Ca2 through extracellular Ca2
influx and ongoing intracellular Ca2mobilization. Biochem. J. 247:695–
700.
21. Intlekofer AM, et al. 2005. Effector and memory CD8 T cell fate cou-
pled by T-bet and eomesodermin. Nat. Immunol. 6:1236 –1244.
22. Jabbari A, Harty JT. 2006. Secondary memory CD8 T cells are more
protective but slower to acquire a central-memory phenotype. J. Exp.
Med. 203:919 –932.
23. Jonsson TJ, Johnson LC, Lowther WT. 2008. Structure of the sulphire-
doxin-peroxiredoxin complex reveals an essential repair embrace. Nature
451:98 –101.
24. Joshi NS, et al. 2007. Inflammation directs memory precursor and short-
lived effector CD8() T cell fates via the graded expression of T-bet tran-
scription factor. Immunity 27:281–295.
25. Kusmartsev S, Nefedova Y, Yoder D, Gabrilovich DI. 2004. Antigen-
specific inhibition of CD8 T cell response by immature myeloid cells in
cancer is mediated by reactive oxygen species. J. Immunol. 172:989 –999.
26. Kwon J, et al. 2005. Receptor-stimulated oxidation of SHP-2 promotes
T-cell adhesion through SLP-76-ADAP. EMBO J. 24:2331–2341.
27. Laniewski NG, Grayson JM. 2004. Antioxidant treatment reduces expan-
sion and contraction of antigen-specific CD8T cells during primary but
not secondary viral infection. J. Virol. 78:11246 –11257.
28. Lee TH, et al. 2003. Peroxiredoxin II is essential for sustaining life span of
erythrocytes in mice. Blood 101:5033–5038.
29. Low FM, Hampton MB, Peskin AV, Winterbourn CC. 2007. Peroxire-
doxin 2 functions as a noncatalytic scavenger of low-level hydrogen per-
oxide in the erythrocyte. Blood 109:2611–2617.
30. Matthews JR, Wakasugi N, Virelizier JL, Yodoi J, Hay RT. 1992.
Thioredoxin regulates the DNA binding activity of NF-kappa B by reduc-
tion of a disulphide bond involving cysteine 62. Nucleic Acids Res. 20:
3821–3830.
31. May JM, de Haen C. 1979. Insulin-stimulated intracellular hydrogen
peroxide production in rat epididymal fat cells. J. Biol. Chem. 254:2214 –
2220.
32. Meng TC, Buckley DA, Galic S, Tiganis T, Tonks NK. 2004. Regulation
of insulin signaling through reversible oxidation of the protein-tyrosine
phosphatases TC45 and PTP1B. J. Biol. Chem. 279:37716 –37725.
33. Michalek RD, et al. 2007. The requirement of reversible cysteine sulfenic
Michalek et al.












acid formation for T cell activation and function. J. Immunol. 179:6456 –
6467.
34. Moon EY, et al. 2006. T lymphocytes and dendritic cells are activated by
the deletion of peroxiredoxin II (Prx II) gene. Immunol. Lett. 102:184 –
190.
35. Murali-Krishna K, Ahmed R. 2000. Cutting edge: naive T cells masquer-
ading as memory cells. J. Immunol. 165:1733–1737.
36. Murali-Krishna K, et al. 1998. Counting antigen-specific CD8 T cells: a
reevaluation of bystander activation during viral infection. Immunity
8:177–187.
37. Mustelin T, Coggeshall KM, Isakov N, Altman A. 1990. T cell antigen
receptor-mediated activation of phospholipase C requires tyrosine phos-
phorylation. Science 247:1584 –1587.
38. Nishi T, et al. 2002. Spatial redox regulation of a critical cysteine residue
of NF-kappa B in vivo. J. Biol. Chem. 277:44548 – 44556.
39. Pearce EL, et al. 2009. Enhancing CD8 T-cell memory by modulating
fatty acid metabolism. Nature 460:103–107.
40. Perl A, Gergely P, Jr, Banki K. 2004. Mitochondrial dysfunction in T cells
of patients with systemic lupus erythematosus. Int. Rev. Immunol. 23:
293–313.
41. Piganelli JD, et al. 2002. A metalloporphyrin-based superoxide dismutase
mimic inhibits adoptive transfer of autoimmune diabetes by a diabeto-
genic T-cell clone. Diabetes 51:347–355.
42. Rutishauser RL, et al. 2009. Transcriptional repressor Blimp-1 promotes
CD8() T cell terminal differentiation and represses the acquisition of
central memory T cell properties. Immunity 31:296 –308.
43. Shlomai J. 2010. Redox control of protein-DNA interactions: from mo-
lecular mechanisms to significance in signal transduction, gene expres-
sion, and DNA replication. Antioxid. Redox Signal. 13:1429 –1476.
44. Tebo AE, et al. 2005. Rapid recruitment of virus-specific CD8 T cells
restructures immunodominance during protective secondary responses.
J. Virol. 79:12703–12713.
45. Wherry EJ. 2011. T cell exhaustion. Nat. Immunol. 12:492– 499.
46. Wood ZA, Poole LB, Karplus PA. 2003. Peroxiredoxin evolution and the
regulation of hydrogen peroxide signaling. Science 300:650 – 653.
47. Wood ZA, Schroder E, Robin Harris J, Poole LB. 2003. Structure,
mechanism and regulation of peroxiredoxins. Trends Biochem. Sci. 28:
32– 40.
48. Xanthoudakis S, Curran T. 1992. Identification and characterization of
Ref-1, a nuclear protein that facilitates AP-1 DNA-binding activity.
EMBO J. 11:653– 665.
49. Yang CS, et al. 2007. Roles of peroxiredoxin II in the regulation of pro-
inflammatory responses to LPS and protection against endotoxin-
induced lethal shock. J. Exp. Med. 204:583–594.
50. Yang CY, et al. 2011. The transcriptional regulators Id2 and Id3 control
the formation of distinct memory CD8() T cell subsets. Nat. Immunol.
12:1221–1229.
51. Yi JS, Holbrook BC, Michalek RD, Laniewski NG, Grayson JM. 2006.
Electron transport complex I is required for CD8 T cell function. J.
Immunol. 177:852– 862.
52. Zenewicz LA, Foulds KE, Jiang J, Fan X, Shen H. 2002. Nonsecreted
bacterial proteins induce recall CD8 T cell responses but do not serve as
protective antigens. J. Immunol. 169:5805–5812.
53. Zhang N, Bevan MJ. 2011. CD8() T cells: foot soldiers of the immune
system. Immunity 35:161–168.
Peroxiredoxin II Regulates T Cell Responses




ctober 12, 2016 by NO
VA SO
UTHEASTERN UNIV
http://jvi.asm.org/
D
ow
nloaded from
 
